Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF
Status:
Completed
Trial end date:
2018-01-29
Target enrollment:
Participant gender:
Summary
This study evaluates the ability of the drug sildenafil to improved exercise capacity,
cardiac performance during exercise, and quality of life in patients with moderate to severe
CF lung disease. 3/4 of the subjects will receive sildenafil and 1/4 will receive placebo.